LB Pharmaceuticals (LBRX)
Develops LB-102 for schizophrenia, bipolar depression, and related neuropsychiatric disorders.
Something off on this page? Send us feedback.
Develops LB-102, an oral amisulpride-derived antipsychotic candidate, across schizophrenia, bipolar depression, and planned adjunctive depression studies. The company has no approved products or revenue yet, and its model depends on clinical readouts, regulatory approval, and future commercialization or partnering.
Builds a clinical-stage neuropsychiatry business around LB-102, an oral methylated amisulpride-derived benzamide. The program is being developed first for acute schizophrenia and bipolar depression, with adjunctive major depressive disorder planned as a later expansion path.
Owns global rights to LB-102, intends to retain US commercialization rights, and may evaluate collaborations outside the United States. The company currently has no approved commercial products and has not recognized revenue since inception.
Execution depends on clinical readouts for the NOVA-2 schizophrenia trial and ILLUMINATE-1 bipolar depression trial, followed by regulatory approval and commercialization or partnering. Operations are reported as one segment.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 24, 2026 | H.C. Wainwright | Reiterate | Buy | $45 | $60 |
| Aug 13, 2026 | Stifel Nicolaus | Target | $40 | $53 | |
| Aug 12, 2026 | BMO Capital | Reiterate | Outperform | $46 | $54 |
| Aug 3, 2026 | Piper Sandler | Reiterate | Overweight | $78 | |
| Jul 20, 2026 | BMO Capital | Initiate | Outperform | $46 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $327.8M · Total debt $5.2M · Total assets $361.7M · Shareholders' equity $332.3M
- Revenue
- $0
- Operating income
- −$53.9M
- Net income
- −$51.6M
No dividends on record.
| Institutions117 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 104.45% | 29.95M shares | |
| Adds to | 104.45% |
28.68M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 104.45%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Deep Track Capital, LPInstitution | 11.69% | 3.35M | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Institution | 9.53% | 2.73M | 13Fas of Jun 30, 2026 |
Ra Capital Management, L.P.Institution | 7.70% | 2.21M | 13Fas of Jun 30, 2026 |
Trails Edge Capital Partners, LPInstitution | 5.31% | 1.52M | 13Fas of Jun 30, 2026 |
Commodore Capital LPInstitution | 5.23% | 1.50M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- AbbVie
Multi-indication Vraylar overlap across psychosis and mood
- Johnson & Johnson
Caplyta and Invega anchor broad schizophrenia and mood overlap
- Bristol-Myers Squibb
Cobenfy challenges schizophrenia launch positioning with novel biology
- Alkermes
Lybalvi targets oral antipsychotic use in schizophrenia and bipolar I
- Neurocrine Biosciences
Late-stage muscarinic schizophrenia pipeline pressure
- Axsome Therapeutics
Auvelity narrows overlap to the adjunctive MDD expansion path
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| LB Pharmaceuticals | $51.00 | +3.16% | $1.42B | — | — | — | — |
| AbbVie | $262.35 | +0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Johnson & Johnson | $275.70 | +0.17% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Bristol-Myers Squibb | $67.50 | −0.23% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Alkermes | $47.74 | +1.14% | $8.01B | 124.6 | — | 4.8 | +27.0% |
| Neurocrine Biosciences | $157.79 | +0.01% | $15.87B | 23.1 | 17.3 | 4.7 | +39.5% |
| Axsome Therapeutics | $212.18 | +1.08% | $10.80B | — | 1,800.7 | 13.9 | +44.2% |
| Median | 31.9 | 17.3 | 5.8 | +18.6% |